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Abstract
Purpose There are growing concerns with the widely used glucocorticoids during the Coronavirus disease-19 (COVID-
19) pandemic due to the associated immunosuppressive effects, which may increase the risk of COVID-19 infection and 
worsen COVID-19 patient outcome. Heavily affecting orthopaedics, the pandemic led to delay and cancellation of almost all 
surgical cases, and procedures including perioperative intra-articular corticosteroid injections (ICIs) saw similar decreases. 
However, the benefits of ICI treatments during the pandemic may outweigh these potential risks, and their continued use 
may be warranted.
Methods A literature search was conducted, and all relevant articles including original articles and reviews were identified 
and considered in full for inclusion, and analysed with expert opinion. Epidemiological statistics and medical guidelines 
were consulted from relevant authorities.
Results ICIs allow a targeted approach on the affected joint and are effective in reducing pain while improving functional 
outcome and patient quality-of-life. ICIs delay the requirement for surgery, accommodating for the increased healthcare 
burden during the pandemic, while reducing postoperative hospital stay, bringing significant financial benefits. However, 
ICIs can exert systemic effects and suppress the immune system. ICIs may increase the risk of COVID-19 infection and 
reduce the efficacy of COVID-19 vaccinations, leading to important public health implications.
Conclusion Perioperative ICI treatments may bring significant, multifaceted benefits during the pandemic. However, ICIs 
increase the risk of infection, and perioperative COVID-19 is associated with mortality. The use of ICIs during the COVID-19 
pandemic should therefore be considered carefully on an individual patient basis, weighing the associated risks and benefits.
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Introduction
The use of intra-articular corticosteroid injections (ICIs) 
started in the early 1950s [1] and is now routinely used for 
management of joint pain and therapeutic treatment across 
a broad range of conditions [2–4]. ICI treatments allow 
symptomatic relief and show therapeutic efficacy when 
administered to almost all major areas of the body, includ-
ing the joints of the upper limb (shoulder, elbow, wrist and 
hand), lower limb (knee, ankle and foot), facet joints of the 
spine, the sacroiliac joint, the coccyx, and the hip, leading to 
its widespread use with broad implications [4]. In particular, 
perioperative ICIs are commonly used for pain relief, allow-
ing better recovery of function postoperatively and improved 
patient quality-of-life [5, 6]. Perioperative is defined as the 
medical care from the time of considering surgery through to 
the postoperative period where the patient strives to obtain 
a full recovery (preoperative, intraoperative and postopera-
tive) [7]. Nevertheless, due to the potential danger of infec-
tions associated with steroid-mediated immunosuppression 
[8–12], the contemporary COVID-19 pandemic has insti-
gated significant additional risks that need to be addressed 
when considering ICI use.
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The Coronavirus disease-19 (COVID-19) pandemic is 
caused by the severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2), a novel coronavirus transmitted 
via respiratory droplets, and was first identified in late 
2019 in Wuhan, China [13]. As estimated by the WHO, 
there are more than 110 million confirmed cases glob-
ally, with 2.5 million deaths worldwide as of February 
2021 [14]. Disease severity in COVID-19 patients ranges 
from asymptomatic to life-threatening, with severe dis-
ease and mortality being more common in the elderly and 
in patients with underlying health conditions [15]. Fur-
thermore, a significant proportion of COVID-19 patients 
may continue to experience long-term detrimental effects 
systemically, affecting the lungs, heart, brain, and the 
immune system [16], several weeks or months after the 
initial infection. The pandemic imposed an unprecedented 
burden on healthcare worldwide, forcing healthcare provi-
sion and practice to adapt globally [17–19]. In particular, 
the use of immunosuppressive agents, including the widely 
used corticosteroids, may heighten the risk of viral infec-
tions and increase COVID-19 severity [15, 20–23]. Perio-
perative use of ICIs must be carefully evaluated, and the 
impact on patient outcome needs to be established.
Surgical procedures have been particularly affected by the 
COVID-19 pandemic [24, 25]. Many countries made the dif-
ficult decision to postpone or cancel most elective surgeries, 
to better direct medical personnel and resources to combat 
the pandemic [26, 27]. In particular, orthopaedic procedures 
have been heavily impacted. Over a 12-week period of peak 
healthcare disruption, a projected 28.4 million surgical oper-
ations would be cancelled globally, of which 6.3 million are 
non-emergency orthopaedic surgeries [24]. Orthopaedics is 
predicted to be the most heavily affected surgical specialty 
worldwide, with the highest cancellation rate (at 82%) out 
of all surgical specialties. Hospital beds are prioritised for 
COVID-19 patients, and surgical trainees are redeployed to 
reinforce medical specialties in treating COVID-19 patients 
[28], including orthopaedic trainees across the UK [29, 30]. 
As of February 2021, 10 million patients are awaiting sur-
gery in the UK, a dramatic increase from 4 million pre-pan-
demic [26]. Recognising the growing concerns of large-scale 
cancellation of non-emergency procedures [31, 32], elective 
surgeries had resumed since the latter half of 2020, albeit at 
much reduced capacities [26]. Healthcare services, and how 
perioperative care is delivered, had to adapt accordingly to 
provide the best care for patients. Perioperative ICIs may 
play an important role in improving symptom control and 
patient quality-of-life during the delay to elective surger-
ies, for example for elective joint replacements commonly 
performed for arthritis. Importantly, reassessing the safety 
and efficacy of these common perioperative management 
strategies employed prior to the pandemic, including ICIs, 
to adapt to the current pandemic is paramount.
The aim of this article was to review the benefits and risks 
associated with perioperative ICIs during the COVID-19 
pandemic in light of recent evidence, with specific focus on 
the impact by the pandemic, along with medical, financial 
and public health implications. The potential interactions 
between ICIs and the immune response against SARS-
CoV-2 is also discussed and is of high relevance with 
important impact on the ongoing COVID-19 vaccination 
programme.
Methods
A literature search was first conducted on PubMed in Janu-
ary 2021, and again in February 2021, and all the relevant 
articles in the English language, including original articles 
and reviews, were identified. All non-peer-reviewed arti-
cles were excluded. Key search terms used were “steroid”, 
“intra-articular injection”, “COVID-19”, “SARS-CoV2”, 
“pandemic”, “virus”, “immune”, and “vaccine”. No articles 
were excluded based on publication date. A serial screening 
method was adopted due to the large number of candidate 
articles. Initially, article titles were screened for relevance 
to the factors discussed in this narrative review, followed 
by a second round of screening through the abstracts. Rel-
evant articles were then considered in full, and the references 
cited in these articles were additionally screened, before 
inclusion. The World Health Organization (WHO) web-
site was consulted for up-to-date global statistics regarding 
the COVID-19 pandemic and recommended guidelines on 
steroid use during the pandemic. The UK government web-
site, and websites of relevant healthcare bodies including 
the National Health Service (NHS), the National Institute 
for Health and Care Excellence (NICE), were consulted for 
COVID-19 pandemic-related healthcare statistics, healthcare 
guidelines, and details on the UK COVID-19 vaccination 
programme. The PRISMA flow diagram for the literature 
search is presented in the supplementary material.
ICI treatments during the COVID‑19 pandemic
ICI treatments involve the administration of glucocorticoids, 
a class of corticosteroids that binds to the glucocorticoid 
receptor. Glucocorticoids were first used therapeutically 
in humans in 1948 to treat rheumatoid arthritis (RA) [33], 
and ICIs are now commonly used in clinical practice [34]. 
Clinically administered glucocorticoids are similar in struc-
ture and function to endogenous cortisol, exerting potent 
anti-inflammatory effects in a dose-dependent manner [35]. 
Due to their widespread action on various cell types, clini-
cal use of glucocorticoids has been limited by the broad 
range of potential adverse effects. In particular, the pio-
neering study by Fauci et al. in the 1970s identified that 
glucocorticoid administration leads to lymphopenia and 
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immunosuppression [36], and steroid use is associated with 
increased risk of infection both in the community and in 
hospital settings [8–12]. Importantly, the increased risk of 
infection is not limited to systemic steroid use, with grow-
ing evidence demonstrating that local administration of ster-
oids also heightens infection risk [37, 38]. Accordingly, in 
patients with rotator cuff tendinosis, a single corticosteroid 
injection up to a month prior to surgery increased the risk 
of postoperative infections twofold [37]. The use of steroids 
in the contemporary COVID-19 pandemic thus needs to be 
exercised with caution.
Regulating bodies including the National Health Service 
(NHS), the British Orthopaedic Association, and the Faculty 
of Pain Medicine, have raised concerns on the immunosup-
pressive effects of corticosteroids, issuing specific guidance 
accordingly to limit the use of steroid injections during the 
COVID-19 pandemic [39–41]. Clinicians are advised to 
maintain awareness of the risks associated with corticoster-
oid injections during the COVID-19 pandemic, and to assess 
the risk to benefit ratio for each patient on an individual 
basis. Specifically, ICIs should only be used in inflammatory 
conditions where there is active synovitis and at the lowest 
clinical effective dose. For musculoskeletal pain manage-
ment, ICIs may only be used if other methods, including 
simple analgesia, splinting, active modification, and exercise 
prove ineffective, in addition to a high degree of pain and 
disability projected to have a significant impact on patient 
health and wellbeing [40]. Strictly, injected steroids should 
not be administered in the presence of an infection.
The guidance is welcomed, as studies suggest steroids 
are often misused clinically without definitive evidence on 
safety and efficacy [42, 43]. Often underappreciated, local 
administration of steroids can exert systemic effects [44], 
where a single dose of 40 mg of methylprednisolone is suf-
ficient for complete hypothalamic–pituitary–adrenal (HPA) 
suppression. This is well within the range of 4-80 mg meth-
ylprednisolone routinely used clinically through ICIs [45]. 
Others have similarly found that a single dose of ICI can 
suppress the HPA axis systemically [46, 47]. Strikingly, 
increased duration of systemic suppression is observed after 
ICI treatment compared to oral steroids, due to the slower 
rate of absorption through joint tissue [48]. A 46% mean 
decrease in both C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) was observed in RA patients after 
knee ICI treatment, with the effect lasting up to 6 months 
[49]. Independent studies had found a similar decrease in 
CRP or ESR levels in RA patients post ICI treatment [50, 
51], suggesting systemic anti-inflammatory effects of ICIs. 
In line with this, ICIs decrease pro-inflammatory cytokines 
and inhibit monocyte function systemically [52, 53] and 
increase the risk of infection after knee, hip and shoulder 
arthroscopy [38]. Given that ICIs may lead to systemic 
immunosuppression and increase risk of infection, it should 
be used with caution clinically, more so amid the COVID-19 
pandemic. Further studies are required to better understand 
the interactions between ICI-mediated immunosuppression 
and COVID-19 infections.
ICIs and the immune response against SARS‑CoV‑2
The immune response against SARS-CoV-2 is complex 
(Fig. 1), and despite the rapid advances in recent months, 
much remains to be clarified. Accumulating evidence sug-
gests that both the innate and the adaptive immune sys-
tems play crucial roles in the defence against SARS-CoV-2 
[54], and better understanding of these processes is vital 
to improve patient care and outcome amid the pandemic. 
Specifically, it is crucial to elucidate the impact of corti-
costeroids on the immune response against SARS-CoV-2.
The immune response is effective in clearing SARS-
CoV-2 infections in most patients, with an overall estimated 
death rate of 0.66% [55]. However, mortality rises sharply 
to 40% in patients with severe COVID-19 [56], where 
abnormal immune hyperactivation inflicts indirect host 
damage through widespread lung inflammation and multi-
organ damage [54]. The reason behind this divergence in 
patient immune response against SARS-CoV-2 is unclear, 
but likely relates to the immune dysregulation observed 
in severe COVID-19 patients. Increase in inflammatory 
monocytes correlates with severity of disease [57, 58], and 
recruitment is through chemokines CCL2 and CCL7, both 
of which elevated in fatal COVID-19 cases [59]. Monocytes 
directly contribute to the cytokine storm profile observed in 
severe COVID-19 patients, indicated by a systemic increase 
in interleukin-6 (IL-6), interleukin-8 (IL-8), interferon-γ 
inducible protein 10 (IP-10), monocyte chemoattractant pro-
tein-1 (MCP1), macrophage inflammatory protein-1 alpha 
(MIP1γ, and TNF [54, 60]. In line with this, anti-inflamma-
tory therapies through immunosuppressive glucocorticoids 
decrease mortality in severe COVID-19 patients and should 
be used [61, 62]. Any non-emergency surgery for patients 
that develop severe COVID-19 must be postponed and only 
proceed when medically safe to do so.
While steroid use is advocated in severe COVID-19 cases 
[63], its use in non-COVID-19 patients or in mild and mod-
erate COVID-19 cases should be exercised with caution, 
due to the immunosuppressive effects as indicated by the 
WHO [64]. In mild and moderate COVID-19 patients, ster-
oid use correlates with prolonged duration of fever, delayed 
virus clearance time, severe disease and longer hospitali-
sation [65–68]. Mechanistically, antigen-specific type 1 
immunity driven by T helper type 1 (Th1) and CD8 T cells 
are paramount in mounting a strong multimodal immune 
response against SARS-CoV-2 (Fig. 1), characterised by 
robust interferon-γ (IFNγ) production and a strong B cell-
mediated antibody response [57, 69]. Conversely, patients 
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that develop severe COVID-19 have decreased T cells, and T 
cells show an exhausted phenotype with impaired functions 
[70]. Reduced lymphocyte count is a negative prognostic 
indicator in COVID-19 patients [71]. Given that a single 
dose of ICI reduces systemic blood lymphocyte count, lead-
ing to lymphopenia four hours after injection [52], ICIs may 
impair the host protective response against SARS-CoV-2. 
The systemic and immunosuppressive effects of steroid 
injections may last several weeks [72] and could consequen-
tially expose patients to COVID-19 infection and develop-
ing severe disease. Accordingly, ICIs increases the risk of 
influenza even among vaccinated individuals [23]. In this 
study, the average dose patient received through a single ICI 
was 65.9 mg, with greater than half of the patients receiv-
ing > 80 mg of methylprednisolone or triamcinolone aceto-
nide or equivalent, which is well within the range to cause 
systemic effects [44]. Critically, the risk of patients acquiring 
COVID-19 infection perioperatively should be minimised, 
as perioperative SARS-CoV-2 infection increases mortality 
in both elective and emergency surgical patients [73]. The 
National Institute for Health and Care Excellence (NICE) 
published guidelines for elective patients to follow com-
prehensive social-distancing measures for 14 days, and to 
test for SARS-CoV-2 within 3 days prior to hospital admis-
sion [74]. The threshold for surgery should be heightened 
during the COVID-19 pandemic, and use of perioperative 
ICI must be carefully evaluated. The increased risk associ-
ated with COVID-19 infection must be balanced with the 
consequences of delaying elective surgeries, and the use of 
ICIs should be discussed in conjunction with patients on an 
individual basis.
Impact on patient quality‑of‑life 
during the COVID‑19 pandemic
In light of the adverse effects of systemic glucocorticoid 
treatments, ICI is popular as it allows a localised approach 
with targeted effect on the affected joint [75]. Perioperative 
ICIs are common for a wide range of orthopaedic surgeries, 
both pre- and postoperatively.
Preoperative use of ICI during COVID‑19: delaying 
elective surgery
In osteoarthritis (OA) patients requiring surgery, preopera-
tive ICIs are associated with a delay to TKA from first pres-
entation to clinic by 8 months, and a similar 5-month delay 
for patients that received total hip arthroplasty [76]. This is 
attributed to preoperative ICIs providing comfort, symptom 
alleviation and reducing functional disability. Overall, the 
benefits of the delay in time to surgery from initial clinical 
presentation are twofold. Firstly, it allows patients time to 
prepare for surgery mentally and to make necessary arrange-
ments for social support. Secondly, and specifically related 
to the COVID-19 pandemic where elective surgeries are 
postponed, preoperative ICIs are effective in improving 
patient quality-of-life during the delay to surgery. Reassur-
ingly, studies of patients given ICI during the COVID-19 
pandemic in the UK did not show any increase in COVID-19 
Fig. 1  The immune response dichotomy against SARS-CoV2 infec-
tion in airway epithelial cells leads to cell death and the release of 
damage-associated molecular patterns (DAMPs), including adeno-
sine triphosphate (ATP), DNA, and High Mobility Group Box  1 
(HMGB1), the latter elevated in COVID-19 patients and correlates 
with inferior outcome. DAMPs and SARS-CoV2-derived pathogen-
associated molecular patterns (PAMPs) including viral nucleic acids 
are detected by tissue resident innate immune cells such as mac-
rophages, leading to cytokine production and recruitment of mono-
cytes and NK cells which further amplifies the response. In mild and 
moderate COVID-19 patients (left blue panel),  FABP4+ alveolar 
macrophages and anti-viral NK cells produce IL-12 and interferon-
γIFNγ, respectively, and together with mature dendritic cells, pro-
mote CD4 T cell T helper type 1 (Th1) polarisation and activation 
of antigen-specific CD8 cytotoxic T lymphocytes (CTLs), leading 
to elimination of viral-infected cells. B cells produce antigen-spe-
cific IgM and IgG, which are effective in neutralising the virus, and 
together, this is characteristic of an effective anti-viral type 1 immune 
response, allowing viral clearance and development of immunologi-
cal memory. A similar response is observed after COVID-19 vac-
cination in non-COVID-19 patients. In severe COVID-19 patients 
(right red panel), an inappropriately heightened immune response 
leads to a significant increase in  CCR2+ inflammatory monocytes and 
 FCN1+ inflammatory macrophages, replacing the  FABP4+ alveolar 
macrophages seen in non-severe patients. A positive-feedback loop 
through increased production of chemokines CCL2 and CCL7 fur-
ther recruits inflammatory monocytes and promote the production of 
pro-inflammatory cytokine IL-1γ. In these patients, NK cells show an 
exhausted phenotype, characterised by NKG2A expression, and have 
impaired anti-viral function. Additionally, widespread epithelial dam-
age releases the alarmin IL-33, leading to the characteristic increase 
in group 2 innate lymphoid cells (ILC2s) seen in severe COVID-19 
patients. ILC2s are potent producers of IL-4, IL-5 and IL-13. IL-5 
recruits and activates eosinophils, and increased eosinophils con-
tribute to the inflammatory pathology and correlates with adverse 
outcomes in COVID-19 patients. Altered dendritic cell maturation, 
together with the IL-4 and IL-13 produced by ILC2s, lead to altered 
CD4 T cell activation and subsequent polarisation towards a T helper 
type 2 (Th2) phenotype with impaired anti-viral functions. Th2 cells 
further produces IL-4 and IL-13, which promotes B cell antibody 
class switch to IgE, and the non-neutralising antibodies may facili-
tate SARS-CoV2 infection via antibody-dependent enhancement. 
CD8 T cells show an exhausted phenotype with defective anti-viral 
functions. Together, the heightened inflammatory environment and 
inadequate viral clearance can result in irreversible pulmonary fibro-
sis and perpetuate a cytokine storm, leading to multi-organ damage. 
In severe COVID-19 patients, steroids reduce mortality by dampen-
ing the inappropriately hyperactivated immune response and cytokine 
storm, while its use is contraindicated in mild and moderate COVID-
19 patients where suppression of the protective anti-viral immune 
response may increase disease severity. In non-COVID patients, ster-
oids may increase the risk of infection and decrease the efficacy of 
COVID-19 vaccinations [54, 57–59, 64, 69, 70, 99, 102–105]. This 
figure was created using templates by Servier Medical Art, licensed 
under a Creative Commons Attribution 3.0 Unported License (https:// 
smart. servi er. com/)
◂
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infection or adverse effects [77, 78]; therefore, ICI may be a 
safe and viable option. Of note, while ICI clinics may also 
work at reduced capacities during the pandemic, reinstating 
ICI clinics could be a practical and more feasible approach 
to combat the significant delays in elective surgeries.
Postoperative use of ICI during COVID‑19: 
post‑operative pain management
Postoperative ICIs reduce pain and swelling and improve 
range of motion after TKA [6]. Improving patient quality-of-
life is paramount, as 50% of patients suffering from chronic 
pain have associated psychological distress [79]. OA is one 
of the top ten most debilitating diseases worldwide [80], 
causing significant pain with 60% of patients awaiting knee 
replacement surgery showing signs of clinical depression 
[26]. Clinical depression may further rise to 90% in patients 
suffering from orthopaedic-related axial pain. Patients diag-
nosed with mental disorders have increased risk of acquir-
ing COVID-19 [81] and are more likely to develop severe 
disease [82]. Furthermore, severe postoperative pain is 
associated with suppressed immune function, and may pre-
dispose to infection [83]. Use of ICIs may improve patient 
health both physically and mentally and thus achieve better 
quality-of-life amid the pandemic and should be considered 
after discussing and assessing each patient and their specific 
circumstances on an individual basis.
There is an inherent fear for a potential rise in self harm 
or suicide rate during the COVID-19 pandemic. While cur-
rent existing reports had found no increase in suicide rates 
in relation to the pandemic [84], it is essential to remain 
vigilant, as a potential increasing trend in certain vulnerable 
groups may be masked by an overall unchanging suicide 
rate. Strikingly, patients with arthritis have significantly 
increased risk for suicide with 46% higher odds than those 
without arthritis [85]. Among the arthritis patients, those 
currently experiencing chronic pain had increased risk 
of suicide compared to those without pain (odds ratio of 
1.5). The delay in elective surgeries due to the pandemic is 
unprecedented and can lead to prolonged suffering of pain 
in arthritis patients awaiting joint replacement surgeries. The 
American Academy of Orthopaedic Surgeons had suggested 
that preoperative ICIs should be considered for pain manage-
ment in surgical arthritis patients during the delay to surgery 
[86]. The use of ICIs can improve pain management and may 
be effective in reducing suicide rates in arthritis patients. 
Extended suffering during the delay to surgery for elective 
patients should not be forgotten, and increasing the capacity 
of ICI clinics during the pandemic should be considered as 
a feasible temporary solution. Better symptomatic control 
and pain management is more important than ever amid the 
pandemic, and ICIs are an effective treatment modality that 
can be employed to achieve this.
Financial implications of perioperative ICIs 
amid the COVID‑19 pandemic
The COVID-19 pandemic had imposed significant finan-
cial burden on healthcare systems worldwide, with an esti-
mated £40 billion extra healthcare service cost per year on 
the NHS [87]. The cost-effectiveness of treatment modali-
ties needs to be considered. A recent UK-based study con-
cluded that addition of ICI and lidocaine to standard hip 
OA treatment significantly improved function and incurred 
less cost (£161.59 per patient) over a 6-month period [88], 
attributed to the higher quality-adjusted life-years. In a ran-
domised control trial (RCT), sonographic guidance for knee 
ICIs reduced procedural pain, doubled the responder rate, 
increased the therapeutic duration by 36% while reducing 
cost by 58% in responders per year [89]. Use of sonographic 
guidance over traditional anatomy landmark methods during 
ICIs directly improves clinical outcome and cost-effective-
ness and should be used whenever appropriate [90]. Another 
UK study found steroid injections to be cost-effective com-
pared to physiotherapy, with an average saving of £43.32 
per patient while outcomes were similar [91]. Alternatively, 
intra-articular injection of ketorolac produced similar degree 
of pain relief to ICI while saving cost in a small study and 
may be considered [92]. Strikingly, perioperative corticos-
teroid injection prior to TKA shortens mean hospital stay by 
25% in a RCT [93]. This is desirable as reducing hospitalisa-
tion time decreases the risk of hospital-acquired COVID-19, 
accommodates for the increased medical demand amid the 
pandemic [94], and has important financial implications on 
cost-savings from reduced hospital stay [95, 96].
Public health implications of ICI treatments 
on the COVID‑19 vaccination programme
Global roll-out of COVID-19 vaccines plays a critical role 
in combating the pandemic. The comprehensive, tiered UK 
vaccination programme prioritises the most clinically vul-
nerable, to protect those that are at highest risk of severe 
COVID-19 outcomes [97]. Factors associated with worse 
COVID-19 prognosis, including reduced physical activity, 
increased age and body mass index, are associated with 
orthopaedic conditions such as OA where ICIs are rou-
tinely used [98]. Of concern, ICIs may reduce the efficacy 
of COVID-19 vaccinations at clinically used doses [99], 
due to the potential immunosuppressive effects on the pro-
tective type 1 immune response (Fig. 1), observed both 
in natural COVID-19 infections [57] and after COVID-
19 vaccination [69]. While more studies are required to 
assess the specific effects of ICIs on COVID-19 vaccina-
tions, previous studies identified ICIs to reduce the effi-
cacy of influenza vaccination [23]. Suboptimal response 
to COVID-19 vaccination will have significant negative 
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Fig. 2  Implications of 
intra-articular corticosteroid 
injections amid the Corona-
virus disease-19 (COVID-19) 
pandemic. The positive and 
negative implications of ICI 
treatment during the COVID-19 
pandemic, along with recent 
guidelines by relevant authori-
ties, are summarised in the 
infographic
Pros and Cons of 
Perioperative Intra-articular 
Corticosteroid Injections (ICI) Treatment 
Amid the COVID-19 Pandemic
Potential positive implications of ICI treatment 
during the COVID-19 pandemic
Potential negative implications of ICI treatment during 
the COVID-19 pandemic
Guidelines on ICI treatments during COVID-19 pandemic 
Improve patient quality of life
    Better pain management 
    Improve functional outcome postoperatively 
    May reduce suicide risk
    May reduce mental health disorders 
Financial benefits
    Reduce hospitalisation time
    Cost-effective
Delay the need of surgery from initial clinical presentation
    Allows patients time to prepare for surgery mentally, and to organise necessary
    social support




ARMA (in conjunction with BOA, BSR and RAIRDA) 
Clinicians should maintain awareness of the risks associated with steroid 
injections amid the pandemic, and assess the risk: benefit ratio for each patient on 
an individual basis. 
ICIs should only be used in inflammatory conditions where there is active synovitis 
and at the lowest clinical effective dose.
For musculoskeletal pain management, ICIs may only be used if other methods, 
including simple analgesia, splinting, active modification, and exercise prove 
ineffective, in addition to a high degree of pain and disability projected to have a 
significant impact on patient health and wellbeing.
Injected steroids should not be administered in the presence of an infection.
Steroids should not be administered in non-severe COVID-19 patients as 
it may cause harm.
ICIs should be considered for pain management in surgical arthritis patients during 
the delay to surgery.
COVID-19 vaccinations should take priority, and any non-essential steroid 
injections should be deferred by 2 weeks to allow better response to the vaccine.   
Increase risk of infection
In non-severe COVID-19 patients, steroids may increase 
hospitalisation and viral shedding time
May reduce COVID-19 vaccine efficacy if administered within 
two weeks 
May facilitate virus evolution and appearance of vaccine 
escape strains
Immunocompromised patients may be less responsive to 
current COVID-19 therapies eg. Remdesivir
 European Journal of Orthopaedic Surgery & Traumatology
1 3
public health implications and should be avoided at all 
costs. Current guidance in the UK suggests that for elec-
tive patients, COVID-19 vaccinations should take priority 
over any form of steroid injections including ICIs, which 
is advised to be postponed by 2 weeks to allow optimal 
response to the COVID-19 vaccine [99]. Finally, it has 
been suggested that evolution of SARS-CoV2 may be 
accelerated in immunosuppressed individuals, due to the 
suboptimal immune response allowing viral persistence 
[100]. Furthermore, existing COVID-19 therapies, such 
as remdesivir, may be less effective in eradicating SARS-
CoV2 in immunosuppressed individuals leading to persis-
tent infections [101], which may potentially facilitate the 
appearance of vaccine escape strains.
Conclusion
In accordance to recent guidance from the NHS, the thresh-
old for perioperative ICIs should be heightened amid the 
COVID-19 pandemic. Although administered locally, ICIs 
exert systemic anti-inflammatory and immunosuppres-
sive effects at clinically relevant doses and increase the 
risk of perioperative infections. Importantly, perioperative 
SARS-CoV-2 infection should be avoided due to the associ-
ated increase in mortality. ICIs may reduce the efficacy of 
COVID-19 vaccinations, which can have significant public 
health impacts. Equally, while capacities for elective ICI 
procedures during the pandemic may be reduced, reinstating 
perioperative ICIs to improve pain management and patient 
quality-of-life is suggested by the American Academy of 
Orthopaedic Surgeons. ICI treatments may delay the need 
for surgery, while enhancing functional outcome postopera-
tively, and may be cost-effective with important financial 
implications. Arthritis patients have increased risk of sui-
cide, and suicide rate is further increased in those suffering 
from chronic pain. The delay in elective surgeries instigated 
by the pandemic may prolong patient suffering in those 
awaiting joint replacement surgeries. ICIs may allow better 
symptomatic control and pain management during the delay. 
Of note, poorly managed postoperative pain is associated 
with immunosuppression and worse functional outcome. 
Clinical decisions on the use of ICIs should thus be made 
on an individual basis, and discussed with patients to achieve 
the best overall outcome (Fig. 2). It is paramount that flex-
ibilities exist in the guidelines for ICI treatments to best 
accommodate for individual patient circumstances. Future 
research will provide further evidence to better evaluate the 
safety of ICI treatments during the COVID-19 pandemic.
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